Quirino MWL, Pereira MC, Deodato de Souza MDF, Pitta IDR, Da Silva Filho AF, Albuquerque MSDS, Albuquerque APDB, Martins MR, Pitta MGDR, Rêgo MJBDM. Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters.
Eur J Histochem 2021;
65. [PMID:
33666065 PMCID:
PMC7967265 DOI:
10.4081/ejh.2021.3174]
[Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2020] [Accepted: 02/09/2021] [Indexed: 01/03/2023] Open
Abstract
The sialic acid-binding immunoglobulin-type lectin Siglec-15 is a promising target for cancer immunotherapy in several tumor types. The present study aimed to investigate Siglec-15 expression in gastric cancer (GC) patient tissues and to evaluate its clinical value. Siglec-15 expression was evaluated by immunohistochemistry in 71 patients. Siglec-15 staining was observed in tumor cells of 53 (74.64%) patients, with significant association with histologic classification and angiolymphatic invasion (p<0.05). Immunohistochemistry analysis also detected Siglec-15 in tumor-associated stroma cells (macrophages/myeloid cells). There was no significant association with outcome parameters. Siglec-15 expression in well differentiated histological GC tissues and in the tumor microenvironment are potential targets to be further investigated as a novel prognostic factor for GC.
Collapse